These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21933000)

  • 1. The use of continuous glucose monitoring in patients with type 2 diabetes.
    Meade LT
    Diabetes Technol Ther; 2012 Feb; 14(2):190-5. PubMed ID: 21933000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HypoDE: Research Design and Methods of a Randomized Controlled Study Evaluating the Impact of Real-Time CGM Usage on the Frequency of CGM Glucose Values <55 mg/dl in Patients With Type 1 Diabetes and Problematic Hypoglycemia Treated With Multiple Daily Injections.
    Heinemann L; Deiss D; Hermanns N; Graham C; Kaltheuner M; Liebl A; Price D
    J Diabetes Sci Technol; 2015 May; 9(3):651-62. PubMed ID: 25759183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SELF BLOOD GLUCOSE MONITORING UNDERESTIMATES HYPERGLYCEMIA AND HYPOGLYCEMIA AS COMPARED TO CONTINUOUS GLUCOSE MONITORING IN TYPE 1 AND TYPE 2 DIABETES.
    Mangrola D; Cox C; Furman AS; Krishnan S; Karakas SE
    Endocr Pract; 2018 Jan; 24(1):47-52. PubMed ID: 29144814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study.
    Pazos-Couselo M; García-López JM; González-Rodríguez M; Gude F; Mayán-Santos JM; Rodríguez-Segade S; Rodríguez-García J; Casanueva F
    Can J Diabetes; 2015 Oct; 39(5):428-33. PubMed ID: 26254702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of performing morning versus afternoon exercise on glycemic control and hypoglycemia frequency in type 1 diabetes patients on sensor-augmented insulin pump therapy.
    Gomez AM; Gomez C; Aschner P; Veloza A; Muñoz O; Rubio C; Vallejo S
    J Diabetes Sci Technol; 2015 May; 9(3):619-24. PubMed ID: 25555390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies.
    McGill JB; Ahmann A
    Diabetes Technol Ther; 2017 Jun; 19(S3):S3-S12. PubMed ID: 28585875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging diabetes therapies and technologies.
    Moser EG; Morris AA; Garg SK
    Diabetes Res Clin Pract; 2012 Jul; 97(1):16-26. PubMed ID: 22381908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of short-term use of the Guardian RT continuous glucose monitoring system on fear of hypoglycaemia in patients with type 1 diabetes mellitus.
    Davey RJ; Stevens K; Jones TW; Fournier PA
    Prim Care Diabetes; 2012 Apr; 6(1):35-9. PubMed ID: 22047939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number of basal rates required to achieve near-normal basal glucose control in pump-treated type 2 diabetes.
    King AB; Clark D; Wolfe GS
    Diabetes Technol Ther; 2012 Oct; 14(10):900-3. PubMed ID: 22845649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Consensus on Use of Continuous Glucose Monitoring.
    Danne T; Nimri R; Battelino T; Bergenstal RM; Close KL; DeVries JH; Garg S; Heinemann L; Hirsch I; Amiel SA; Beck R; Bosi E; Buckingham B; Cobelli C; Dassau E; Doyle FJ; Heller S; Hovorka R; Jia W; Jones T; Kordonouri O; Kovatchev B; Kowalski A; Laffel L; Maahs D; Murphy HR; Nørgaard K; Parkin CG; Renard E; Saboo B; Scharf M; Tamborlane WV; Weinzimer SA; Phillip M
    Diabetes Care; 2017 Dec; 40(12):1631-1640. PubMed ID: 29162583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of daily glycemic profiles in well controlled children with type 1 diabetes mellitus using a continuous glucose monitoring system.
    Tucholski K; Deja G; Skała-Zamorowska E; Jarosz-Chobot P
    Pediatr Endocrinol Diabetes Metab; 2009; 15(1):29-33. PubMed ID: 19454186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous Glucose Monitoring Versus Capillary Point-of-Care Testing for Inpatient Glycemic Control in Type 2 Diabetes Patients Hospitalized in the General Ward and Treated With a Basal Bolus Insulin Regimen.
    Gómez AM; Umpierrez GE; Muñoz OM; Herrera F; Rubio C; Aschner P; Buendia R
    J Diabetes Sci Technol; 2015 Aug; 10(2):325-9. PubMed ID: 26330394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump system.
    Peyrot M; Rubin RR
    Diabetes Technol Ther; 2009 Jan; 11(1):57-62. PubMed ID: 19132857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM.
    Kesavadev J; Sadikot S; Wangnoo S; Kannampilly J; Saboo B; Aravind SR; Kalra S; Makkar BM; Maji D; Saikia M; Anjana RM; Rajput R; Singh SK; Shah S; Dhruv U; Vishwanathan V
    Diabetes Metab Syndr; 2014; 8(3):187-95. PubMed ID: 25200925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data-driven modeling and prediction of blood glucose dynamics: Machine learning applications in type 1 diabetes.
    Woldaregay AZ; Årsand E; Walderhaug S; Albers D; Mamykina L; Botsis T; Hartvigsen G
    Artif Intell Med; 2019 Jul; 98():109-134. PubMed ID: 31383477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA).
    Moser O; Riddell MC; Eckstein ML; Adolfsson P; Rabasa-Lhoret R; van den Boom L; Gillard P; Nørgaard K; Oliver NS; Zaharieva DP; Battelino T; de Beaufort C; Bergenstal RM; Buckingham B; Cengiz E; Deeb A; Heise T; Heller S; Kowalski AJ; Leelarathna L; Mathieu C; Stettler C; Tauschmann M; Thabit H; Wilmot EG; Sourij H; Smart CE; Jacobs PG; Bracken RM; Mader JK
    Pediatr Diabetes; 2020 Dec; 21(8):1375-1393. PubMed ID: 33047481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inpatient Continuous Glucose Monitoring and Glycemic Outcomes.
    Levitt DL; Silver KD; Spanakis EK
    J Diabetes Sci Technol; 2017 Sep; 11(5):1028-1035. PubMed ID: 28290224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.